Orris
attachment

Questions for this poster

I can see this is a research poster about NK cell immunotherapy. What questions do you have about it? Feel free to ask anything - about the methodology, results, conclusions, or the science behind it - and I'll do my best to answer based on what's shown in the poster and my knowledge of the field.

I have to present. What questions could I be asked?

Reading File
Loading Image
Here is a comprehensive set of questions you are likely to be asked, organized by category:

Science & Mechanism

  1. Why does Abatacept (CTLA4-Ig) affect NK cells? Abatacept blocks CD80/CD86-CD28 co-stimulation on T cells - what is the proposed mechanism by which it influences NK cell effector function?
  2. Why were IL-2, IL-15, IL-18, and CiML-IL chosen specifically? What is the rationale for this cytokine panel - are these clinically relevant concentrations?
  3. What is the difference between IL-15 and CiML-IL priming in this context? The poster shows Aba enhances IL-15 effects but abolishes CiML-IL effects - can you explain mechanistically why these two cytokines diverge?
  4. What does NKG2C+CD56dim represent? Why is this NK cell subset specifically implicated in mediating the Aba + IL-15 effect?
  5. Why was Golgi stop/plug added before cytokine assay? Can you explain that step in your intracellular cytokine staining protocol?

Methodology

  1. Only 12 donors - is this adequately powered? How did you determine this sample size, and what are the statistical limitations?
  2. All samples were from healthy donors - how translatable is this to haploidentical transplant patients? NK cells in post-transplant immunosuppression may behave very differently.
  3. The 5:1 and 1:1 E:T ratios with K562 cells - why K562 specifically? K562 are MHC-I negative; does this reflect a real clinical target?
  4. Why 72 hours vs. 7 days as your two time points? What is the biological justification for these specific time points?
  5. How did you control for T cell contamination in your NK cell isolation? What was your NK cell purity after Dynabead isolation?

Results & Interpretation

  1. Baseline NK cytotoxicity was only 10.1% - is that low? How do you interpret this baseline and does it affect the clinical relevance of the fold-changes?
  2. The Aba + IL-15 combination increased IFN-γ 4-5 fold - is this desirable or could it drive inflammation? How do you contextualize the safety of augmented cytokine release?
  3. Aba significantly increased perforin at 72 hours (p=0.02) but not at 7 days - why the time-limited effect? Does this suggest tachyphylaxis or receptor downregulation?
  4. You showed no impact of Aba on CiML-IL - does this mean CiML-IL drives NK activity through a completely CD28-independent pathway?
  5. The table shows some conditions with very wide IQR ranges - how confident are you in the reproducibility of these results across donors?

Clinical Translation

  1. What is the AbaN15 therapy in the Phase 1/2 study? What population are you targeting - post-haploidentical DLI, relapsed AML, other?
  2. How does this build on the prior CTLA4-Ig DLI work referenced? What gap does this NK-focused work fill that the T cell literature did not address?
  3. What are the safety concerns with giving Abatacept + IL-15 in vivo? IL-15 has significant toxicity at systemic doses.
  4. Is there a GvHD risk with augmented NK cell activity post-haploidentical transplant? How do you separate GvL from GvHD in this context?
  5. What would the clinical delivery look like? Would this be ex vivo NK expansion + Aba, or in vivo Aba administration alongside IL-15?

Broader Context

  1. How does this compare to CAR-NK approaches? What advantage does this cytokine-priming + Aba strategy offer over engineered NK cells?
  2. The references focus heavily on Chakrabarti's own work - what independent validation exists for this approach?
  3. What is the next step if Phase 1/2 fails? Do you have biomarkers that would predict which patients respond?
Tip for your presentation: The questions most likely to come from a knowledgeable audience are #1 (mechanism of Aba on NK cells), #7 (healthy donor translatability), #11 (low baseline cytotoxicity), and #18 (IL-15 toxicity in vivo). Be especially ready to defend the small sample size and the healthy donor model.

https://acrabstracts.org/abstract/a-study-of-natural-killer-cell-subfractions-in-abatacept-therapy-for-rheumatoid-arthritis/

Reading Web Page

NK cell subfractions abatacept rheumatoid arthritis

Searching PubMed

abatacept natural killer cells rheumatoid arthritis

This ACR abstract is very relevant to your poster - it's independent clinical evidence that Abatacept affects NK cell subsets in vivo. Here's how it connects and how you can use it:

What the ACR Abstract Shows

This Japanese study looked at NK cell subfractions (specifically CD57+ cells) in RA patients treated with Abatacept for 52 weeks. Key findings:
  • CD8+/CD57+ cells significantly decreased after 52 weeks of Abatacept (16.9 → 10.2, p=0.004)
  • CD8+/CD11b+ cells also significantly decreased (16.7 → 12.1, p=0.02)
  • CD4+/CD25+ (Treg) dynamics differed between bio-naive patients and those switched from other biologics

How This Supports Your Poster

This abstract gives you in vivo clinical corroboration for what your poster studies in vitro:
  1. Abatacept does affect NK cell biology in real patients - not just in lab conditions with healthy donor PBMCs. If questioned about translational relevance, you can cite this.
  2. CD57 is a marker of NK cell maturity/cytotoxic potency - the CD57+ NK subset that decreases with Abatacept in RA patients overlaps conceptually with the NKG2C+CD56dim (mature cytotoxic) subset your poster identifies as mediating the Aba + IL-15 effect.
  3. The direction appears paradoxical - Abatacept reduces cytotoxic NK subsets in RA (an inflammatory disease), but your poster shows it can enhance NK cytotoxicity in combination with IL-15 in the post-transplant context. This is actually a strong talking point: context matters - immunosuppressive vs. immunostimulatory environments change how Abatacept modulates NK cells.

Anticipate This Question

"In RA patients on Abatacept, NK cells are actually suppressed - doesn't that contradict your findings?"
Your answer: The RA context involves chronic T cell-driven inflammation where Abatacept dampens overall immune activation, reducing mature NK cell numbers. In your model, Abatacept is paired with specific cytokine priming (IL-15), which likely shifts the NK cell response through a different pathway - specifically NKG2C+CD56dim cells, which may be uniquely responsive to IL-15 in a post-transplant milieu. The two settings are not directly comparable.
This is a useful reference to have ready - it shows you are aware of the broader literature and can contextualize your findings within the clinical landscape.
This is a shared conversation. Sign in to Orris to start your own chat.